Mosaic Biosciences
Mosaic Biosciences is a Boulder, Colorado-based biologics discovery CRO providing integrated antibody discovery, protein engineering, cell-based assays, analytics, and translational pharmacology services to biotech, biopharma, pharmaceutical, and academic clients, augmented by proprietary platforms including Atlas FHD mice, SortAI, and PKE.
- Company typePrivate
- Founded2009
- HeadquartersBoulder, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Mosaic Biosciences does
Mosaic Biosciences is a privately held biologics discovery Contract Research Organization (CRO) headquartered in Boulder, Colorado, founded in 2009. The company provides integrated antibody and protein therapeutic discovery services spanning target identification through candidate selection, structured across five core solution areas: Antibody Discovery and Optimization, Protein Design and Engineering, Cell-Based Assays, Protein Sciences and Analytics, and Translational Pharmacology. Its customer base spans emerging and growth-stage biotechnology companies, biopharma organizations, large pharmaceutical R&D groups, and academic research institutions, with named collaborations in ophthalmology (Catalyst Biosciences for Geographic Atrophy, Ingenia Therapeutics for wet AMD) and partnerships such as the Abkyu VHH alliance.
The company differentiates through proprietary technology assets that are uncommon among general CROs, including the Atlas Full Human Diversity (FHD) transgenic mouse platform with over 99 percent V-region coverage and freedom-to-operate design, the PKE (Pharmacokinetic Enhancer) platform for extending vitreous half-life of ocular biologics, proprietary naïve Fab and VHH libraries, and the recently launched SortAI yeast display validation service for AI-generated antibody libraries. Discovery workflows are anchored by high-throughput instrumentation including the Carterra LSAXT HT-SPR platform, with NGS-driven repertoire profiling, hit clustering, and developability analytics embedded throughout. The scientific leadership team includes veterans from Regeneron, Novartis, Pfizer, Biogen, Bristol Myers Squibb, Eleven Biotherapeutics, and Twist Bioscience.
Mosaic operates a sales-led, enterprise field sales GTM motion, engaging partners through direct scientific consultation, dedicated project management, and flexible commercial structures including program-based fee-for-service contracts, milestone- and royalty-based technology access (notably royalty-free access to the Atlas FHD mouse), and collaborative research arrangements. Revenue is generated through professional services contracts, licensing and royalty structures tied to partnered programs, and collaborative research agreements. Pricing is quote-based and not publicly disclosed. The company has raised approximately $14.7 million across multiple funding rounds since 2011, including a $11.4 million round in June 2022 led by Telegraph Hill Partners. In September 2025, founder Marty Stanton transitioned out of the CEO role and was succeeded by Jean-Pierre Wery, the former co-founder and CEO of Crown Bioscience.
Mosaic Biosciences firmographics
Firmographics- Name
- Mosaic Biosciences
- Legal name
- Mosaic Biosciences, Inc.
- Website
- https://mosaicbio.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mosaic Biosciences is a Boulder, Colorado-based biologics discovery CRO providing integrated antibody discovery, protein engineering, cell-based assays, analytics, and translational pharmacology services to biotech, biopharma, pharmaceutical, and academic clients, augmented by proprietary platforms including Atlas FHD mice, SortAI, and PKE.
- Ownership category
- akta.pro rank
Mosaic Biosciences industry classification
Industry- Product category
- Biologics Discovery CRO Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industry
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where Mosaic Biosciences is headquartered
LocationHeadquarters
- HQ city
- Boulder
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Mosaic Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Contract Research Services: Mosaic operates as a biologics discovery CRO providing fee-for-service research programs across antibody discovery, protein engineering, cell-based assays, protein sciences, and pharmacology. Services are structured through program-based partnerships with defined milestones, timelines, and costs.
- Technology Access Partnerships: Targeted use of Mosaic discovery technologies to augment internal capabilities of biotech and pharma partners. Includes milestone-based, royalty-free access to Atlas FHD mouse platform.
- Collaborative Research: Joint scientific exploration of novel targets, modalities, or discovery approaches through shared experimental design and execution with milestone and royalty-based commercial models.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | SortAI - Full Engagement |
| Other | Multi-year contract | SortAI - Sequence Enrichment |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Mosaic Biosciences product offering
Product offeringCore offering
Mosaic Biosciences operates as an integrated biologics discovery Contract Research Organization (CRO), providing fee-for-service research programs spanning antibody discovery, protein engineering, cell-based assays, protein sciences, and translational pharmacology. The company combines proprietary platforms (Atlas FHD transgenic mice, SortAI yeast display validation, PKE half-life extension) with advanced instrumentation to move therapeutic candidates from target identification through preclinical candidate selection for biotech, biopharma, and pharmaceutical partners.
Product overview
Mosaic Biosciences operates as an integrated biologics discovery CRO offering a platform-plus-modules architecture. The core platform spans five interconnected service areas: Antibody Discovery & Optimization (in vivo and in vitro workflows), Protein Design & Engineering (computational and experimental protein engineering), Cell Based Assays (functional in vitro characterization), Protein Sciences & Analytics (biophysical and developability assessment), and Pharmacology (translational PK/PD studies). These core services are augmented by specialized offerings including SortAI (yeast display validation for AI-generated antibody libraries), the Atlas™ FHD Mouse transgenic platform for fully-human antibody discovery, the Carterra HT-SPR high-throughput SPR instrument for kinetics and epitope binning, and VHH/nanobody discovery services through the Abkyu partnership. The platform enables seamless progression from target through candidate selection, with services engageable independently or as an integrated discovery program.
Differentiator
Problem solved
Functional benefit
Brands
- SortAI: A wet lab validation service built for AI-designed antibody libraries, enabling yeast-based screening at library scale for AI drug discovery companies.
- Atlas™ Full Human Diversity Mouse
- PKE (Pharmacokinetic Enhancer)
Products and services
- Antibody Discovery & Optimization In vivo and in vitro antibody discovery workflows integrating immunization strategies across multiple species and platforms with display-based optimization and function-first analytics to generate, optimize, and triage leads that are both biologically relevant and developable. Designed for biotech and pharma partners pursuing therapeutic antibody candidates.
- Protein Design & Engineering Computational and experimental protein engineering platform combining in silico modeling with expression, screening, and biophysical characterization to advance engineered protein therapeutics. Includes library-based optimization using yeast display for affinity maturation, specificity refinement, and developability improvement.
- Cell Based Assays Fit-for-purpose in vitro cell-based assay development supporting functional characterization, mechanism-of-action studies, and potency evaluation of biologic therapeutics. Includes cellular response readouts, receptor engagement studies, and stable cell line generation using CRISPR and overexpression approaches.
- Protein Sciences & Analytics Comprehensive protein characterization and developability assessment services including binding assays (SPR, BLI kinetics), biophysical characterization (HPLC, interferometry, mass spectrometry), and analytical workflows to evaluate structure, function, and manufacturability of protein therapeutics.
- Pharmacology Translational pharmacology services integrating PK/PD and bioanalytical assays to support informed translational decisions and efficient in vivo study design. Includes fit-for-purpose ELISA development, sample extraction, tissue-specific method qualification, biomarker quantification, and cross-reactivity assessment.
- SortAI Yeast display-based validation service designed specifically for AI-generated antibody sequence panels. Converts computationally designed sequence panels into ranked, training-ready biological data including positive binders, negative populations, and functional signal, before committing to full recombinant protein production. Targeted at AI drug discovery companies.
- Atlas Full Human Diversity (FHD) Mouse Platform Fully human transgenic mouse platform delivering human-like antibody repertoires with broad epitope coverage and developable binders. V-regions cover more than 99% of known and expressed human sequences and are designed to avoid patented or FTO-excluded variants. Available through milestone and royalty-free access model for partners seeking freedom to operate.
- VHH Discovery Services Single-domain antibody (nanobody) discovery capabilities offered through partnership with Abkyu. Combines camelid immunization, immune repertoire analysis, and VHH engineering with Mosaic's integrated downstream workflows including functional screening, developability assessment, and lead selection.
Quantifiable outcome
- 55% increase in ocular half-life achieved through PEGylation engineering on protease therapeutic
- +6 more outcomes
Companies that use Mosaic Biosciences
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles5 records
Mosaic Biosciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature8 records
Mosaic Biosciences partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- AbkyucorePreferred partnership combining Mosaic's integrated biologics platform with Abkyu's specialized in vivo VHH expertise. The collaboration delivers seamless end-to-end pathway for clients pursuing single-domain antibodies (VHHs), including camelid immunization, immune repertoire analysis, VHH engineering and optimization, and integrated functional screening. Clients gain access to full VHH-focused capabilities through a single coordinated discovery experience.
- CarterracoreMosaic added Carterra LSAXT high-throughput surface plasmon resonance (HT-SPR) instrument to its discovery platform. The technology enables rapid, high-sensitivity analysis of protein-protein and antibody-antigen interactions with industry-leading throughput, supporting lead identification and candidate selection across oncology, immunology, and rare disease programs.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Mosaic Biosciences competitors and assessment
Company assessmentDirect peers
- AbCellera Biologics: Vancouver-based antibody discovery CRO with proprietary transgenic platforms, AI-driven screening, and integrated discovery-to-manufacturing capabilities. Most directly comparable to Mosaic as a specialty biologics discovery CRO competing for the same biotech and biopharma customers.
- Adimab: Leading yeast-display-based antibody discovery CRO offering fully human antibody lead generation for biotech and pharma partners. Directly comparable to Mosaic's phage/yeast display and integrated biologics discovery offering.
- GenScript: Global biologics services provider with antibody discovery, protein engineering, and cell therapy capabilities. Competes with Mosaic for biotech and biopharma discovery outsourcing budgets across multiple modalities.
- Twist Bioscience: DNA synthesis and antibody discovery platform; acquired Abveris (Mosaic CSO Tracey Mullen's former company) to build in vivo antibody discovery services. Direct peer in antibody discovery CRO services and an important talent/competitive reference point.
Broad incumbents
- Charles River Laboratories: Large, diversified CRO offering discovery, safety assessment, and manufacturing services across small molecule and biologics. Overlaps with Mosaic's biologics discovery work as part of a much broader portfolio rather than as a specialty focus.
- WuXi Biologics: Global biologics CDMO and discovery services provider with end-to-end capabilities from discovery through commercial manufacturing. Competes for biologics discovery outsourcing and represents the large-scale alternative to Mosaic's specialty model.
- Lonza Group: Global biologics CDMO with growing discovery services footprint. Represents a large, capital-rich incumbent that can absorb discovery programs and bundle them with downstream manufacturing.
- Catalent: Global biologics CDMO with biologics development and analytical services. Overlaps with Mosaic's protein sciences, cell line, and analytics offerings as part of a much broader services portfolio.
Others
- Bio-Techne: Life science reagents and tools provider including protein and antibody products. Adjacent rather than directly competitive, but a comparable ecosystem participant whose tools underpin Mosaic's discovery workflows.
- Eurofins Scientific: Global bioanalytical and CRO services network with biologics characterization, bioassay, and pharmacology capabilities. Adjacent to Mosaic's Protein Sciences & Analytics and Pharmacology service lines.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Mosaic Biosciences social profiles
Digital presenceMosaic Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mosaic Biosciences leadership team
Management profileNumber of profiles
Profiles8 records
Mosaic Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mosaic Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mosaic Biosciences
What does Mosaic Biosciences do?
Mosaic Biosciences operates as an integrated biologics discovery Contract Research Organization (CRO), providing fee-for-service research programs spanning antibody discovery, protein engineering, cell-based assays, protein sciences, and translational pharmacology. The company combines proprietary platforms (Atlas FHD transgenic mice, SortAI yeast display validation, PKE half-life extension) with advanced instrumentation to move therapeutic candidates from target identification through preclinical candidate selection for biotech, biopharma, and pharmaceutical partners.
Is Mosaic Biosciences a public or private company?
Mosaic Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mosaic Biosciences founded?
Mosaic Biosciences was founded in 2009. It employs 11 to 50 people.
Where is Mosaic Biosciences based?
Mosaic Biosciences is headquartered in Boulder, United States, in the North America region.
How does Mosaic Biosciences make money?
Three revenue lines are on record. Contract Research Services are the primary driver. The others are technology Access Partnerships and collaborative Research.
Who are Mosaic Biosciences's main competitors?
Direct peers on record are AbCellera Biologics, Adimab, GenScript and Twist Bioscience. Broad incumbents are Charles River Laboratories, WuXi Biologics, Lonza Group and Catalent. Others are Bio-Techne and Eurofins Scientific.
Does Mosaic Biosciences have an API?
No public API is recorded for Mosaic Biosciences.
What industry is Mosaic Biosciences in?
Mosaic Biosciences's product category is Biologics Discovery CRO Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 5417 and its SIC code is 8731.